Doctors wrote a case report about two patients who received lung transplants from the same donor. Both patients later developed Legionnaires' disease, a serious type of pneumonia caused by bacteria. The report suggests the infection might have been passed from the donor to the recipients through the transplanted lungs. This is a very rare situation described in just two people. The report does not provide details about how the patients were treated or their final health outcomes. It also does not report any other safety issues or complications from the transplants. The main reason to be careful with this information is that it is only a description of two cases. It does not prove that the donor definitely caused the infections, and it cannot tell us how often this might happen. Readers should understand this is an early alert about a possible risk in organ transplantation. It highlights the importance of donor screening, but it does not change current medical practice. More research would be needed to understand if this is a common concern.
Two lung transplant recipients developed Legionnaires' disease from a single donorTwo lung transplant recipients developed Legionnaires' disease from same donor
AI-generated summary of the cited source, checked by automated accuracy review. How we work
A case report describes two lung transplant recipients who developed Legionnaires' disease. Both patients received lung transplants from the same donor. The report documents 2 cases of Legionnaires' disease in these recipients, suggesting possible transmission from the donor. No effect sizes, p-values, or confidence intervals were reported for this association.
Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. The report does not provide information on the clinical course or outcomes for the two patients.
Key limitations include the descriptive, non-comparative nature of a case report. No comparator group was studied, and the evidence does not establish causality for donor-to-recipient transmission. The sample size was only 2 patients, and follow-up duration was not reported.
For clinical practice, this report highlights a potential risk that warrants awareness during donor evaluation and post-transplant monitoring. However, the evidence is preliminary and descriptive, offering no guidance on prevention or management strategies. Funding sources and author conflicts of interest were not reported.
View Original Abstract ↓
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
Related in Pulmonology & Critical Care
From Other Specialties
